Angiotensin II and endothelin induce inflammation and thereby promote hypertension-induced end-organ damage

Clinical Nephrology

Volumn 60, Issue SUPPL.1, 2003, Pages

  Muller D N ^a   Fiebeler, A ^a   Park, J K ^a   Dechend, R ^a   Luft, F C ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Angiotensin II; End organ damage; Endothelin; Inflammation; NF B

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; BOSENTAN; DARUSENTAN; DEOXYCORTICOSTERONE ACETATE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROSTANE DERIVATIVE; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; PROTEIN INHIBITOR; PYRROLIDINE DITHIOCARBAMATE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL MODEL; CLINICAL STUDY; CLINICAL TRIAL; DRUG INHIBITION; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; EXPERIMENTAL ANIMAL; GENE EXPRESSION; HUMAN; HYPERTENSION; INFLAMMATION; LIVER INJURY; MEDICAL RESEARCH; NONHUMAN; RECEPTOR BLOCKING; REGULATORY MECHANISM; REVIEW; STRUCTURE ANALYSIS; TREATMENT PLANNING;

ANGIOTENSIN II; ANIMALS; ENDOTHELIN-1; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; NF-KAPPA B; VASCULITIS;

EID: 0038721322     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP 2001 Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol 280: R1388-R1392
2. Asai K, Kudej RK, Takagi G, Kudej AB, Natividad F, Shen YT, Vatner DE, Vatner SF 2001 Paradoxically enhanced endothelin-B receptor-mediated vasoconstriction. in conscious old monkeys. Circulation 103: 2382-2386
3. Barton M, Vos I, Shaw S, Boer P, D'Uscio LV, Grone HJ, Rabelink TJ, Lattmann T, Moreau P, Luscher TF 2000 Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol 11: 835-845
4. Beevers G, Lip GYH, O'Brien E 2001 The pathophysiology of hypertension. BMJ 322: 912-916
5. Benigni A, Perico N, Remuzzi G 2000 Endothelin antagonists and renal protection. J Cardiovasc Pharmacol 35 (4 Suppl 2): S75-78
6. Benigni A, Perico N, Remuzzi G 2001 Research an renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Curr Opin Nephrol Hypertens 10: 1-6
7. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC 2001 Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37 (Part 2): 781-786
8. Boemke W, Hocher B, Schleyer N, Krebs MO, Kaczmarczyk G 2001 Hemodynamic, renal and endocrine responses to acute ETA blockade at different Ang II plasma levels. Am J Physiol 280: R1322-R1331
9. Boffa JJ, Tharaux PL, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C 1999 Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence of an endothelin-mediated mechanism. Circulation 100: 1901-1908
10. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C 2001 Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 37: 490-496
11. Bohlender J, Gerbaulet S, Kramer J, Gross M, Kirchengast M, Dietz R 2000 Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension. 35: 992-997
12. Brasier AR, Ron D, Tate JE, Habener JF 1990 A family of constitutive C/EBP-like DNA binding proteins attenuate the IL-1α-induced, NFkappaB-mediated trans-activation of the angiotensinogen gene acute-phase response element. EMBO J 9: 3933-3944
13. Browatzki M, Schmidt J, Kubler W, Kranzhofer R 2000 Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 95: 98-105
14. Bur D, Dale GE, Oefner C 2001 A three-dimensional model of endothelin-converting enzyme (ECE) based an the X-ray structure of neutral endopeptidase 24.11 (NEP) Protein. Eng 14: 337-341
15. Coo Z, Cooper ME, Wu LL, Cox AJ, Jandeleit-Dahm K, Kelly DJ, Gilbert RE 2000 Blockade of the renin-angiotensin and endothelin systems an progressive renal injury. Hypertension 36: 561-568
16. Cheng CP, Ukai T, Onishi K, Ohte N, Suzuki M, Zhang ZS, Cheng HJ, Tachibana H, Igawa A, Little LC 2001 The role of Ang II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure. Am J Physiol 280: H1853-H1860
17. Eckman EA, Reed DK, Eckman CB 2001 Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J Biol Chem 276: 24540-24548
18. Eddy AA 2000 Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301
19. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA 1999 To114 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104: 271-280
20. Gilbert RE, Rumble JR, Cao Z, Cox AJ, van Eeden P, Allen TJ, Kelly DJ, Cooper ME 2000 Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy and epidermal growth factor expression in experimental diabetes. Circ Res 86: 158-165
21. Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F, Egido J 2001 Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension 37: 1171-1178
22. Ishizuka T, Takamizawa-Matsumoto M, Suzuki K, Kurita A 1999 Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alpha-stimulated vascular endothelial cells. Eur J Pharmacol 369: 237-245
23. Iwanaga Y, Kihara Y, Inagaki K, Onozawa Y, Yoneda T, Kataoka K, Sasayama S 2001 Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation 104: 606-612
24. Kedzierski RM, Yanagisawa M 2001 Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41: 851-876
25. Khush RS, Lemaitre B 2000 Genes that fight infection: what the Drosophila genome says about animal immunity. Trends Genet 10: 442-449
26. Kimbrell DA, Beutler B 2001 The evolution and genetics of innate immunity. Nat Rev Genet 4: 256-267
27. Muenter K, Dashwood MR 2001 Blockade of the renin-angiotensin and endothelin systems an progressive renal injury. Hypertension 37: E13
28. Müller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F, Theuer J, Breu V, Mackman N, Luther T, Schneider W, Gulba D, Ganten D, Haller H, Luft FC 2000 Angiotensin II (AT1) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol 157: 111-122
29. Müller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, Breu V, Loffler BM, Ganten D, Schneider W, Haller H, Luft FC 2000 Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 36: 282-290
30. Müller DN, Mullally A, Dechend R, Park JK, Fiebeler A, Pilz B, Loffler BM, Blum-Kaelin D, Masur S, Dehmlow H, Aebi JD, Haller H, Luft FC 2002 Related articles, links abstract: Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension 40: 840-846
31. Müller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finekenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC 2002 Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 161: 1679-1693
32. Müller DN, Dechend R, Mervaala EMA, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC 2000 NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35: 193-201
33. Müller DN, Heissmeyer V, Decherd R, Hampich F, Park JK, Fiebeler A, Shagdarsuren E, Theuer J, Pilz B, Breu V, Schroer K, Ganten D, Dietz R, Haller H, Scheidereit C, Luft FC 2001 Aspirin inhibits NF-κB and protects from angiotensin II-induced organ damage. FASEB J 15: 1822-1824
34. Ortiz MC, Sanabria E, Manriquez MC, Romero JC, Juncos LA 2001 Role of endothelin and isoprostanes in slow pressor responses to angiotensin II. Hypertension 37: 505-510
35. Park JB, Schiffrin EL 2001 Et(a) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 37: 1444-1449
36. Pollock DM, Derebail VK, Yamamoto T, Pollock JS 2000 Combined effects of AT(1) and ET(A) receptor antagonists, candesartan and A-127722 in DOCA-salt hypertensive rats. Gen Pharmacol 34: 337-342
37. Purcell NH, Tang G, Yu C, Mercurio F, Didonato JA, Lin A 2001 Activation of NF-κB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 98: 6668-6673
38. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, Stier G, Sattler M, Schleicher E, Speiser W, Nawroth PP 2000 Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49: 1561-1570
39. Ruggenenti P, Schieppati A, Remuzzi G 2001 Progression, remission, regression of chronic renal diseases. Lancet 357: 1601-1608
40. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J 2001 Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol 158: 1743-1756
41. Schiffrin EL 2001 Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14 (Part 2): S83-S89
42. Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, Bandinelli B, Bertolozzi I, Polidori G, Toscano T, Maccherini M, Modesti PA 2001 Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 88: 961-968
43. Spieker LE, Noll G, Ruschitzka FT, Lüscher TF 2001 Endothelin receptor antagonists in congestive heart failure: a new principle for the future? J Am Coll Cardiol 37: 1493-1505
44. Taal MW, Chertow GM, Rennke HG, Gurnani A, Jiang T, Shahsafaei A, Troy JL, Brenner BM, Mackenzie HS 2001 Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol 280: F343-355
45. Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule JC 2000 Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 36: 330-336
46. Tzanidis A, Lim S, Hannan RD, See F, Ugoni AM, Krum H 2001 Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor b1. J Mol Cell Cardiol 33: 969-981
47. Uhlmann D, Witzigmann H, Senninger N, Hauss J, Spiegel HU 2001 Protective role of an endothelin-converting enzyme inhibitor (FR901533) in hepatic ischemia/reperfusion. Injury Microvasc Res 62:43-54
48. van Wamel AJ, Ruwhof C, van der Valk-Kokshoom LE, Schrier PI, van der Laarse A 2001 The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol Cell Biochem 218: 113-124
49. Watanabe T, Pakala R, Katagiri T, Benedict CR 2001 Angiotensin II and serotonin potentiate endothelin-1-induced vascular smooth muscle cell proliferation. J Hypertens 19: 731-739
50. Wong NLM, Tsui JKC 2001 Angiotensin regulates endothelin-B receptor in rat inner medullary collecting duct. Metabolism 50: 661-666
51. Woods M, Wood EG, Mitchell JA, Warner TD 2000 Signal transduction pathways involved in cytokine stimulation of endothelin-1 release from human vascular smooth muscle cells. J Cardiovasc Pharmacol 36 (5 Suppl 1): S407-409
52. Zhang G, Ghosh S 2001 Toll-like receptor-mediated NF-kappaB activation a phylogenetically conserved paradigm in innate immunity. J Clin Invest 107: 13-19